ACP
LXRX icon

Acuta Capital Partners’s Lexicon Pharmaceuticals LXRX Stock Holding History

Acuta Capital Partners’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-32,500
Closed -$321K – 74
2017
Q4 		$321K Sell
32,500
-7,500
-19% -$77.9K 0.06% 67
2017
Q3 		$492K Buy
+40,000
New +$591K 0.09% 58

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

Acuta Capital Partners's LXRX Position: Q4 2015 in Review

Acuta Capital Partners sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2015, closing a stake of 400,000 shares — an estimated $4.3M sold.

Acuta Capital Partners first reported a position in LXRX in Q3 2015 and held it in 1 quarter. The position peaked at $4.3M in Q3 2015. 118 funds tracked by Wall St. Rank hold LXRX as of Q4 2015.

  • Acuta Capital Partners reported no remaining Lexicon Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Acuta Capital Partners sold 400,000 Lexicon Pharmaceuticals shares in Q4 2015, an estimated $4.3M.
  • Acuta Capital Partners first reported a position in Lexicon Pharmaceuticals in Q3 2015 and held it in 1 quarter.
  • Acuta Capital Partners's Lexicon Pharmaceuticals position peaked at $4.3M in Q3 2015.
  • 118 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2015.

Based on Acuta Capital Partners's 13F filing for Q4 2015, filed 12 Feb 2016.